Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
Don't Waste Another Minute: Dump These 3 F-Rated Stocks Now
04:24pm, Tuesday, 19'th Dec 2023
Investors need to understand and be able to steer clear of companies that have a poor future outlook. Whether from reduced financial guidance, overall financial instability, management issues, or rele
Is Moderna Stock A Buy After Retaking Its 50-Day Line On Strong Cancer Vaccine Sales?
03:14pm, Tuesday, 19'th Dec 2023
Is Moderna stock a buy after announcing promising results for its Merck-tied cancer vaccine? Is MRNA stock a buy right now?
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
05:50am, Monday, 18'th Dec 2023
BioNTech's pipeline should take center stage going forward. JD.com is dirt cheap after a big sell-off.
Moderna Just Took a Step Closer to Its Product Launch Goal. Is the Stock a Buy?
05:00am, Monday, 18'th Dec 2023
Investors have shied away from buying Moderna shares as demand for its coronavirus vaccine declines. But the biotech has set high goals, aiming to release many new products during the next few years.
3 S&P 500 Stocks That Are About to Get Absolutely Crushed
05:00pm, Saturday, 16'th Dec 2023
The bulls look to be firmly in control of the stock market now. The U.S. Federal Reserve has pivoted away from its monetary tightening regime and signaled three interest rate cuts in 2024.
Moderna: MRNA-4157 Cancer Vaccine Data Points To A Future Beyond Spikevax
05:16am, Saturday, 16'th Dec 2023
Moderna and Merck reported data regarding their cutting-edge mRNA-based skin cancer regimen that includes the former's cancer vaccine, MRNA-4157. This mRNA-based skin cancer regimen represents one of
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
01:32pm, Friday, 15'th Dec 2023
Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
Moderna RSV vaccine more than 80% effective, study shows
08:29am, Friday, 15'th Dec 2023
Moderna Inc.'s MRNA, +9.25% investigational vaccine for respiratory syncytial virus is 84% effective against the lower respiratory tract illness linked with the virus, according to phase 3 study data
Moderna CEO talks skin cancer vaccine: It's a big deal for melanoma patients
06:00am, Friday, 15'th Dec 2023
Moderna (MRNA) shares are surging Thursday after the company announced positive mid-stage trial data showing its experimental cancer vaccine, used in combination with Merck's (MRK) immunotherapy Keytr
MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer
04:30pm, Thursday, 14'th Dec 2023
Moderna (NASDAQ: MRNA ) has been on a rough trajectory in recent days. Indeed, continuous declines in MRNA stock earlier this week have hurt investor sentiment in the large-cap biotechnology company.
Moderna shares soar on cancer drug results
03:16pm, Thursday, 14'th Dec 2023
CNBC's Angelica Peebles joins 'Power Lunch' to report on Moderna's experimental cancer vaccine.
Moderna-Merck Vaccine for Skin Cancer Shows Positive Results; Moderna Stock Jumps
01:55pm, Thursday, 14'th Dec 2023
A personalized vaccine developed by Moderna (MRNA) and Merck (MRK) showed significant positive results in treating skin cancer in high risk patients.
Midday Movers: Moderna Soars on Vaccine Trial, Adobe Slumps on Guidance Miss
01:10pm, Thursday, 14'th Dec 2023
U.S. equities were up at midday, with the Dow adding to its record high set yesterday, as rising retail sales added to enthusiasm surrounding the Federal Reserve's comments signaling rate cuts next ye
Moderna's cancer vaccine shows promise, but regulatory hurdles loom
11:46am, Thursday, 14'th Dec 2023
Moderna Therapeutics Inc (NASDAQ:MRNA) revealed positive data from its second cut of the cancer vaccine for adjuvant melanoma in combination with Keytruda. The report indicates a 49% recurrence-free s
Moderna Stock Soars After Cancer Vaccine's Strong Test Results
11:35am, Thursday, 14'th Dec 2023
Moderna's new mRNA vaccine reduces the chance of relapse or death of skin cancer by half when paired with Merck's immunotherapy drug Keytruda, new data shows, marking a step forward in the developing
